SHYNDEC(SH:600420) Xin Lang Cai Jing·2026-01-12 09:25Core Viewpoint - The company has received approval from the National Medical Products Administration for a new specification of injectable Piperacillin Sodium and for its consistency evaluation as a generic drug [1] Group 1: Product Approval - The company's wholly-owned subsidiary, China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd., has been granted a supplement approval notice for injectable Piperacillin Sodium [1] - The newly approved specification includes 1.0g, in addition to existing 0.5g and 2.0g formulations [1] Group 2: Indications and Uses - Injectable Piperacillin Sodium is primarily indicated for infections caused by sensitive Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter species [1] - It is used to treat conditions such as sepsis, upper urinary tract and complicated urinary tract infections, respiratory infections, biliary infections, abdominal infections, pelvic infections, as well as skin and soft tissue infections [1] - The drug can also be used in combination with aminoglycosides for infections in patients with neutropenic immunodeficiency [1]